Table 3

Correlation of PD-1+CD8+ T cells (peripheral blood) and Gal-3+ tumor cells with favorable clinical outcomes following belapectin+pembrolizumab immunotherapy

Group*CR/PRSD/PDP value†
High-risk, n (%)0 (0)8 (89)0.0004
Low-risk, n (%)8 (100)1 (11)
  • *Group including high-risk and low-risk subgroups defined by Classification and Regression Tree (CART) analysis: high-risk if %PD-1+/CD8 Teff < 24 or %PD-1+/CD8 Teff > 24 and Gal-3+/tumor < 1186; low-risk if %PD-1+/CD8 Teff > 24 and Gal-3+/tumor > 1186.

  • †Fisher exact test.

  • CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.